Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

BACKGROUND: PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-L1 IHC, each developed with a different ICI. We set to test if next generation...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Main Authors: Conroy, Jeffrey M., Pabla, Sarabjot, Nesline, Mary K., Glenn, Sean T., Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Wang, Yirong, Lenzo, Felicia L., Bshara, Wiam, Khalil, Maya, Dy, Grace K., Madden, Katherine G., Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J., Zhu, Jason, Labriola, Matthew, Marin, Daniele, McCall, Shannon J., Clarke, Jeffrey, George, Daniel J., Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, de la Cruz-Merino, Luis, Singavi, Arun, George, Ben, MacKinnon, Alexander C., Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Kasuganti, Deepa, Shah, Neel, Day, Roger, Galluzzi, Lorenzo, Gardner, Mark, Morrison, Carl
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6346512/
https://ncbi.nlm.nih.gov/pubmed/30678715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0489-5
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki